Orgenesis
Zan Fleming is the current Director at Orgenesis. Prior to this, they served as the Chief Medical Officer and Chairman of the Board at Exsulin from January 2005 to December 2011. There, they were responsible for leading clinical development and regulatory strategy for INGAP Peptide and other islet regeneration therapies. Prior to their work at Exsulin, Zan Fleming was employed at Kinexum from January 1986 to December 1998 as a supervisory physician.
Dr. Zan Fleming received their M.D. from Emory University School of Medicine and completed a fellowship in endocrinology at Vanderbilt University School of Medicine. Zan is currently a fellow in metabolism at the National Institutes of Health.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Orgenesis
Orgenesis is a pioneering global biotech company featuring a unique Cell & Gene Therapy Biotech Platform. The company is focused on unlocking the power of cell and gene therapies with this platform to provide life-changing treatments at the Point of Care (POCare) to large numbers of patients at drastically reduced costs.